Budget impact of Ifezuntirgene inilparvovec
1 evidence topic · 12 sources
Summary
ICER's model analysis plan uses a placeholder price for AMT-130, and the report holds no budget impact model for the product. The inputs on which a plan's budget would depend are available from ICER's model analysis plan, analyst estimates, and published prices of approved gene therapies.
- Eligible population: ICER multiplies a U.S. prevalence of approximately 40,000 people in 2020 (a prevalence rate of approximately 0.012%) by the approximately 62.7% of people with Huntington's disease in SF stage 1 or 2 and applies it to a U.S. population of approximately 342 million averaged over 2026-2030, giving 25,811 eligible patients. ICER assumes that 20% of these patients would initiate treatment in each of the five years, or 5,162 patients per year. An exploratory preclinical population of 100,000 people, with 20,000 initiating treatment per year, is derived from approximately 200,000 people at risk and the 50% likelihood of inheriting the mutation. In a study population of 38.4 million individuals who met a continuous enrollment requirement, the prevalence rate was 6.7 per 100,000 in 2020 and 9.4 per 100,000 in 2024.
- Price: Leerink analysts estimated a U.S. price of $1.7 million if approved. ICER cites estimates ranging from $1,700,000 by Leerink Partners to $2,500,000 - $3,500,000 by IPD analytics and uses the midpoint of $2,600,000 as a placeholder price, with an administration price of $24,138.83.
- Budget impact method: ICER will estimate budget impact at the placeholder price and at threshold prices of $50,000, $100,000, $150,000, and $200,000 per evLY gained, with undiscounted costs over a five-year time horizon. Its potential budget impact threshold for 2026-2027 is approximately $709 million per year for new drugs.
- Comparator prices: Zolgensma, a one-time treatment, launched at a list price of $2.125 million, the gene therapy Hemgenix at $3.5 million, Roctavian at a wholesale acquisition cost of $2.9 million, the gene therapy Elevidys at a wholesale acquisition cost of $3.2 million, and the gene therapy Beqvez at $3.5 million; the U.S. wholesale acquisition cost of eladocagene exuparvovec-tneq is $3,950,000. A pharmacist quoted at the Elevidys launch stated that gene therapy prices range from $2.1 million to $3.5 million. BioMarin announced that it will voluntarily remove Roctavian from the market, and Beqvez was discontinued.
- Reference budget impact analysis: in a CSL Behring-funded analysis of etranacogene dezaparvovec at $3,500,000 in a hypothetical 1-million-member plan, an estimated 1.8 people were eligible, and gradual uptake produced a cumulative 5-year budget impact of $848,509, with incremental per-member per-month costs of $0.007 to $0.023; 100% uptake in year 1 produced an incremental annual cost of $4.843 million or $0.40 PMPM.